Study of dTACE-HAIC with Bevacizumab and Atezolizumab for Large Intermediate to Advanced Hepatocellular Carcinoma

What this Trial Is About

This research aims to evaluate the effectiveness and safety of combining drug-eluting transcatheter arterial embolization and hepatic arterial infusion chemotherapy dTACE-HAIC with the drugs Bevacizumab and Atezolizumab for patients who have intermediate to advanced large hepatocellular carcinoma HCC. The study focuses on patients with large tumors who cannot undergo radical therapy, exploring a treatment approach that combines locoregional therapy with targeted and immune-based medications. The treatment involves a procedure where a microcatheter is carefully inserted into the artery feeding the tumor, followed by the delivery of drug-eluting microspheres. Patients then receive hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin every four weeks. Additionally, oral Lenvatinib is given daily, and Toripalimab is administered intravenously every two weeks. This study tests the combination of these procedures and medications to assess their impact on large hepatocellular carcinoma. Participants will undergo evaluations including imaging and lab tests to monitor tumor response and safety throughout the study. Researchers will measure the objective response rate after 12 months as the primary outcome, with progression-free survival at 12 months and overall survival at 24 months as secondary outcomes. The study is expected to last until June 2026, with ongoing safety and efficacy monitoring during this period.

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma